Development of molecular diagnostic platform for α 0 -thalassemia 44.6 kb (Chiang Rai, -- CR ) deletion in individuals with microcytic red blood cells across Thailand.

Introduction: The α ⁰ -thalassemia 44.6 kb or Chiang Rai (-- ^CR ) deletion has been reported in northern Thailand and is capable of causing hemoglobin (Hb) H disease and a lethal α-thalassemia genotype, Hb Bart's hydrops fetalis, in this region. However, there are no current data regarding the frequency of -- ^CR nationwide due to a lack of effective diagnostic assay. Therefore, this study aimed to develop a reliable platform for simultaneous genotyping of -- ^CR and two common α ⁰ -thalassemias in Thailand (-- ^SEA and -- ^THAI ) and investigate the frequency of -- ^CR across Thailand.
Methods: Multiplex gap-PCR assay and five renewable plasmid DNA controls for -- ^CR , -- ^SEA , -- ^THAI , α2-globin (HBA2), and β-actin (ACTB) were newly developed and validated with reference methods. The developed assay was further tested on 1046 unrelated individuals with a reduced mean corpuscular volume (MCV) of less than 75 fl for investigating genotypic and allelic spectrum of -- ^CR .
Results: Our developed assay showed 100% concordance with reference methods. The results were valid and reproducible throughout hundreds of reactions. Comparison of the genotypic and allelic spectra revealed that heterozygous -- ^SEA (-- ^SEA /αα) and -- ^SEA alleles were dominant with the frequency of 22.85% (239/1046) and 13.34% (279/2092), respectively. Of these, -- ^THAI and -- ^CR were relatively rare in this population and comparable to each other with the allelic frequency of 0.14% (3/2092).
Conclusion: This study successfully established a reliable molecular diagnostic platform for genotyping of -- ^CR , -- ^SEA , and -- ^THAI in a single reaction. Additionally, we demonstrated the frequency of -- ^CR in Thailand for the first time and provided knowledge basis for the planning of severe α-thalassemia prevention and control programs in Thailand, where thalassemia is endemic.
(© 2023 John Wiley & Sons Ltd/University College London.)